| 1 | | | |
|----------|---|-------------------------|---|
| 2 | <a ,"="" has<br="" href="mailto:</td><td></td><td>Formatted: Font: 9 pt, Font color: Text 1, Complex Script Font: Arial, 9 pt, Not Bold</td></tr><tr><td>3</td><td></td><td></td><td>Formatted: Font: 9 pt, Font color: Text 1, Complex Script Font: Arial, 9 pt, Not Bold</td></tr><tr><td>т 5</td><td></td><td>Ϊ</td><td>Formatted: Font: 12 pt, Complex Script Font: 12 pt</td></tr><tr><td>C</td><td></td><td>1</td><td>Formatted: Font: Bold</td></tr><tr><td>6</td><td></td><td>1</td><td>Formatted: Font: Bold</td></tr><tr><td>Ū</td><td></td><td><math>\langle \rangle</math></td><td>Formatted: Font: Not Bold</td></tr><tr><td>7</td><td></td><td></td><td>Formatted: Superscript</td></tr><tr><td>8</td><td></td><td><math>\langle \rangle</math></td><td>Formatted: Font: Not Italic</td></tr><tr><td>-</td><td></td><td><math> \rangle</math></td><td>Formatted: Font: Italic, Superscript</td></tr><tr><td>9 10 11</td><td></td><td></td><td>Comment [CE1]: AQ: Please check the Author and Affiliation sections – Affiliation 1 has not been linked to any of the authors and in author section, none of the author, except ">been linked to any affiliation. | | |
| 12 | | X | Formatted: Font: Not Bold |
| 14 | | | Formatted: Font: +Headings, 9 pt, Complex Script Font: 9 pt, Bold |
| 15 | | | Formatted: Font: Not Italic |
| 16 | | | Comment [CE2]: AQ: Please provide the Telephone number of the corresponding author. |
| 17 | < <u>REC_ACC></u> Received: Dec 22, 2019; <u>Accepted:</u> Jun 19, 2020 | $\langle \cdot \rangle$ | Formatted: Font: Not Italic |
| 18 | < <u>CITATION LINE</u> | $\left(\right)$ | Formatted: Font: 9 pt, Complex Script Font: 9 pt, Bold |
| 19 20 | <u><copyright_line>Copyright: © 2020</copyright_line></u> , et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any | | Formatted: Font: 9 pt, Complex Script Font: 9 pt, Bold |
| 21 | <u>ABS_TL></u> ABSTRACT | | Formatted: Default Paragraph Font, Font: (Default) +Body, 12 pt, Complex Script Font: +Body, 12 pt, Not Bold |
| 23 24 | <a href="mailto:</td><td></td><td>Formatted: Font: Bold, No underline, Font color: Auto</td></tr><tr><td>25 26</td><td>rural population. The acute pharmacological test of PJB recorded no death or any signs of toxicity even at the highest dose of 4000 mg/Kg kg body weight. To find out the effect of chronic administration of PJB on serum chemistry profile, it was</td><td></td><td>Formatted: Font: Bold, No underline, Font color: Auto</td></tr><tr><td>27 28</td><td>administered chronically to the male Sprague-Dawley rats at a dose of 400 mg/kg. After 28 days of chronic administration of the PJB preparation_the serum chemistry profile, composed of a battery of tests, allowed for evaluation of several body systems</td><td></td><td>Comment [CE3]: PE: Please provide the citation line for this article.</td></tr><tr><td>29 30</td><td>and assessment of metabolic disturbances. The results of <u>the effect of chronic administration of PJB on serum chemistry</u> profilewere as follows, the effect on serum chemistry profile after chronic administration are thus: There is was a statistically</td><td></td><td>Formatted: Font: Bold, No underline, Font color: Auto</td></tr><tr><td>31</td><td>highly significant (p=0.003) decrease in the total protein in the serum of the male rat-s-[9.45% decrease]There is was</td><td></td><td>Formatted: Font: Bold</td></tr><tr><td>32</td><td>statistically highly significant (p=0.010) increase in the albumin level in the serum of the male rats-<u>f[24.66% increase].</u> There</td><td><math>\left\ \right\ </math></td><td>Formatted: Font: Bold</td></tr><tr><td>33 34</td><td>ts-wasa statistically very highly significant (p=0.001) decrease in the globulin level in the serum of the male rat<u>st</u>[45.50% decrease]. There is was statistically significant (p=0.015) increase in the albumin (globulin ratio in the serum of the male rat</td><td></td><td>Formatted: Font: Not Bold</td></tr><tr><td>35</td><td>sf(175.19% increase h). There is-wasa statistically significant (p=0.014) increase in the uric acid level in the serum of the male rat-</td><td></td><td>Formatted: Font: Not Bold</td></tr><tr><td>36 37 38</td><td><u>sf</u>[25.16 % increase]). <u><KWD>Keywords</u>:Pijusaballi Rasa, <u>Oe</u>Edema, Ayurvedic, Albumin, Globulin, Uric acidAcid-</td><td></td><td>Comment [CE4]: AQ: In the sentence " pijusaballi<br="">Rasa (PJB) is an Ayurvedic preparation", please be specific about the place of "the rural population" you are referring to (for e.g. Japan, Bangladesh, etc.). | | |
| 39 | | 1 | Formattade Forte Nat Bald |

<H1>INTRODUCTION

Ayurvedic medicines have <u>a</u> reputation as decent and effective remedies for a number of diseases [<u>1</u>]. Currently, the World Health Organization (WHO) has officially recognized and recommended large-scale use of herbal (Unani and Ayurvedic) medicines, particularly in the developing countries, as an alternative system of medicine to deliver health-care services at the primary health-care level [<u>2</u>]. According to WHO, approximately <u>1.5</u> billion people of <u>around</u>the world are now getting treatment treated with these medicines [<u>3</u>]. They <u>also</u> have a good safety profile-<u>also</u> [<u>4</u>].

Pijusaballi Rasa (PJB) is an Ayurvedic preparation which is used as a traditional medicine in the treatment of edema in the rural population [5-11].

Pijusəbəlli RasəPJBis-has been</u>included (pages 246-247) in the

1992 (Approved approved by the Government of

1991) [5].

The use of herbal preparations without any standard dosage along with inadequate scientific studies on their safety profile has raised concerns on their toxicity [12]. That is why; we designed our current experimentdeveloped this study to observe the effect of chronic administration of PJB to Sprague-Dawley rats at a high dose. The objective is to have a better understanding of the potential toxicological profile of the drug and to decide how justifiable the use of this drug is under the stated conditions. The study provides directions for further research as well.

<H1>MATERIALS AND METHODS

<H2>Drugs, Chemicalschemicals, and Reagentsreagents:

For this research work to characterize the Kidney function profile, Pijusaballi rasa (PJB) was collected from Sri .Ketamine

injection was purchased from . Limited, . All other reagents, assay kits, and chemicals used in this work were purchased from Human GmbH, Wiesbaden, Germany.

<<u>H2></u>Experimental <u>Animalsanimals</u>:

Six_to-eight-weeke-old male Sprague-Dawley rats bred and maintained at the animal house of the Department of Pharmacy, University, were used in this hematological experiment. These animals were apparently healthy and <u>each</u> weighed 50-70g. The animals were housed in a well-ventilated clean experimental animal house under constant environmental and adequate nutritional conditions throughout the period of the experiment. They were fed with rat chow prepared according to the formula developed at of Scientific and Industrial Research – Water was provided ad libitum and the animals were maintained at 12 hours day and 12 hours night cycle. All experiments on the rats were carried out in absolute compliance with the ethical guide for care and use of laboratory animals approved by Ethical Review Committee, Faculty of Life Sciences, Department of Pharmacy, University.

<<u>H2></u>Experimental Ddesign

<u><H3>Acute Toxicity toxicity Studystudy</u>:The acute oral pharmacological test was performed fe as perthe guidelines of Organization for Economic Co-operation and Development (OECD) for testing of chemicals with minor modifications (OECD Guideline 425) [13]. Sixteen male nice_Sprague-Dawley_rats(30-40_g_body_weight)_were divided into four groups, of each groupcomprising four animals-each. Different doses (1000-mg/kg, 2000-mg 3000-mg/kg, and 4000 mg/kg) of the experimental drug (PJB) were administered to the rats by stomach tube. The dose was divided into two fractions and given within 12 hours. Then all the experimental animals were observed for mortality and clinical signs of toxicity (general behavior, respiratory pattern, cardiovascular signs, motor activities, reflexes, and changes in skin and fur texture) at 1, 2, 3, and 4 hours and thereafter once a day for the next -<u>3</u>days following PJB administration.

<H3>Chronic toxicity studies: Prior to the experiment, rats were randomly divided into 2-twogroups of 8-eight animals each. One group was treated with PJB and another was used as control. The control animals were administered with distilled water only, at a volume same as the drug ed-administered to the study group for 28 days. For all the pharmacological studies, the drugs were administered per oral route at a dose of 400 mg/Kg body weight [14]. After acclimatization, the Avurvedic medicinal preparation was administered to the rats by intra-gastric syringe between the 10 am to and 12 am daily throughout the study period [15-19]. All the experimental animals were marked carefully on the tail, which helped to uniquely identify them-particularly. By uUsing identification marks, responses were noted separately for a particular period prior to and after the administration [20]

<H3>Blood Samples samples Collection collection and Preparation preparation of Serumserum: At the end of the 28 days treatment period, after 18 hours of fasting, rats from each group were anaesthetized by administration (i.p.) of ketamine (500 mg/kg body weight) after 18 hour fasting [21-2928]. For biochemical analysis, Blood-blood samples were collected from post vena cava of rats into plain sample tubes for serum generation for biochemical analysis[3029]. Serum was obtained after allowing blood to coagulate for 30 minutes and centrifuged centrifugingit at 4000 rpm for 10 minutesusing benchtop centrifuge (MSE Minor, EnglandUK). The supernatant serum samples Formatted: Font: Not Bold

Formatted: Font color: Red

Formatted: Font color: Red

Formatted: Font color: Red

Formatted: Font: Not Italic, Font color: Black, English (United Kingdom)

Formatted: Font color: Red

Formatted: Font: Font color: Red, English (United Kingdom)

Comment [CE5]: AQ: In the sentence "Pijusaballi Rasa (PJB) is an Ayurvedic preparation ...", please be specific about the place of "the rural population" you are referring to (for e.g. Japan, Bangladesh, etc.).

Formatted: Font color: Red

Formatted: Font color: Red

| Comment [CE6]: AQ: In the sentence "The use of herbal preparations .", perhaps it is "possible toxicity" instead of just "toxicity"? |
|---|
| Formatted: Font color: Red |
| Formatted: Font: Not Italic |
| Comment [CE7]: AQ: In the sentence "The objective is to have a better", perhaps it is "to demonstrate" instead of "to decide"? |
| Former Marcha Ford and an Dad |
| Formatted: Font color: Red |
| Formatted: Font: Not Italic |
| Formatted: Font: Not Italic |
| Formatted: Font: Not Italic |
| Formatted: Font color: Red |
| |
| Formatted: Font color: Red |
| Formatted: Font: Not Italic |
| Formatted: Font: Not Italic |
| Formatted: Font: Not Italic |
| Formatted: Font: Not Bold |
| Formatted: Font color: Red |
| Comment [CE8]: AQ: Could "post vena cava" be changed to "posterior vena cava"? |
| Formatted: Font color: Red |
| Formatted: Font: Not Bold |
| |

were collected using dry Pasteur pipette and stored in the refrigerator for further analysis. All analyses were completed within 24 hours of sample collection [3130,3231].

<H3>Determination of Biochemical biochemical Parametersparameters: Biochemical analysis was carried out on serum to assess the state of the liver [3332] and kidney [3433]. Biochemical studies involved analysis of parameters such as Total_total Protein_protein [2534], Albumin_albumin_(by Bromacresol_Bromocresolgreen method) [3635], Creatinine_creatinine [3736], Blood-blood Urea_urea_Nitrogen_nitrogen (BUN) [3837], and Urie-uric Acid_acid [3938]. The absorbance_values of inall the tests were determined using spectrophotometer (UV-Visible Spectrophotometer Model No. UV-1601 PC.).

<H3>Statistical Analysisanalysis: SPSS (Statistical Package for Social Science) Statistics 11.5 package (SPSS Inc., Chicago,IIIL) was used to carry out independent sample <u>t</u>test to analyze the data. All values <u>are-were</u>expressed as mean ± SEM (Standard error of the mean) and p<0.05, p<0.01, <u>and p</u><0.001 were taken as the level of significance.

<<u>H1></u>RESULTS

<u><H2></u>Acute Pharmacological pharmacological Studystudy: The drug (PJB) administered up to a high dose of 4000 mg/kg produced no mortality. Thus the LD50 (Median median Lethal lethal Dosedose) value was found to be greater than 4000 mg/Kg-kg body weight. The animals did not manifest any sign of restlessness, respiratory distress, general irritation, or convulsion. Since PJB is has been in the clinical use for treatment of diseases for many years, a limit test was performed in acute oral toxicity study. According to the OECD test guideline 425, when there is information in support of low toxicity or non-toxicity and low or no immortality nature of the test material, then the limit test at the highest starting dose level (4000 mg/Kg-kg body weight) was conducted. There were no signs of mortality and toxicity-signs observed at 4000 mg/Kg-kg body weight. Therefore, it can be concluded that PJB when administered at single dose is non-toxic and can be used safely in oral formulations.

<H2>Effect of Pijusaballi Rasa (PJB) on Total total Serum serum Proteinprotein, Albuminalbumin, Globulin globulin content, and Aalbumin/G-globulintatio in Male male Ratsrats:

After 28 days of chronic administration of the Pijusaballi Resa (PJB)-preparation, the total protein, albumin content, and the calculated ratio of albumin to globulins, termed the albumin/globulin (A/G) ratio, in serum were determined in the male rats group. In the study, the total protein content in the serum was decreased (9.45%) in the PJB_treated male rats. The decrease in total protein was statistically highly significant (p=0.003).On the contrary, the albumin content was found to be increased (24.66%) in PJB_treated male rats, and it was statistically highly significant (p=0.010), and there was ahighly significant (p=0.001) decrease(45.50%-decr.) in globulin content. As a result the increase (175.19 %) in the Albumin-/Głobulin ratio from their corresponding control values was statisticallysignificant(p=0.015) (Table- $\frac{1}{2}$).

<u><H2>Effect of PJB on Creatininegreatinine</u>, BUN, <u>Ureaurea, and Urie-uric Acid acid level in male rats:</u> The creatinine and <u>blood urea nitrogen(BUN)</u> content in the serum were measured to carry out kidney function test. The <u>levelsseof these</u> two contents

Compounds can provide information about how effective the kidney function is. There was a statistically insignificant increase in the creatinine (7.58% incr, p=0.205) content in serum in the PJB-treated male rats and also statistically insignificant (p=0.200) increase of blood urea nitrogen (BUN) level (11.23% incr, p=0.200) in the serum was noted in comparison to their control group. The increase in BUN/Creatinine creatinine ratio (3.49 % incr) was also statistically insignificant (p=0.702). It was observed that there was a statistically significant (p=0.014) increase (25.16%) in serum uric acid content of PJB-treated male rats in comparison to their control male rats (Table 3).

<H1>DISCUSSION

The formulation of Pijusaballi Rasa (PIB) is included composed of Sutaka (suddhaparada), Gandhaka (suddha), Abhra (abhrakabhasma), Tara (rajatabhasma), Lauha (bhasma), Tangana (suddhatankana), Rasanjana (daruharidra), Maksika (bhasma),Lavanga, Candana (svetacandana), Musta (musta), Patha, Jiraka (Svetajiraka), Dhanyaka, Samanga (Lajjalu), Ativisa, Lodhra, Kutaja, Indrayava (Kutaja), Tvaca (Tvak), Jatiphala, Cirabilva, Kanaka bija (Suddhadhattura), Dadimachada (dadima), Samanga (Lajjalu), and Dhataki, Kustha (Rt.);-_)_contains 6 mg of each of theseingredient-ingredients—and Kesaraja Rasa (bhrngaraja),_) andChagidugdha (ajaksira) Q.S. for bhavana [5-11].

Protein is the important part of all cells and tissues. The total protein test measures the total amount of two classes of proteins found in the fluid portion of blood: albumin and globulin. Albumin helps to prevent fluid leakage from blood vessels and globulins are an important part of immune system [4939]. Drugs such as estrogens, oral contraceptives, and any drug toxic to the liver, can cause a reduction of the total blood protein levels. Thehighly significant decrease of total protein in the PIB_treated experimental population can be due to liver diseases, and kidney kidney problems.Conditions such as hyperthyroidism and thiamine deficiency may also cause low protein levels in the body[4140,4241].

A serum albumin test measures the amount of protein in the clear liquid portion of the blood. This test can help determine if a <u>patient-person</u>has-liver disease-or-kidney disease, or if <u>thea_person's</u> body is not absorbing enough-protein [4342].The highly significant increase of

| Formatted | [1] |
|-------------------------------|----------------|
| Formatted | [2] |
| Comment [CE10]: COMP: Pleas | e insert [30] |
| Formatted | [[3] |
| Formatted | [[31]] |
| Formatted | [32] |
| Formatted | [4] |
| Formatted | [[33]] |
| Formatted | [34] |
| Formatted | [35] |
| Formatted | [36] |
| Formatted | [5] |
| Formatted | [37] |
| Formatted | [[6] |
| Formatted | [7] |
| Formatted | [8] |
| Formatted | [9] |
| Formatted | [[10] |
| Formatted | [11] |
| Formatted | [12] |
| Comment [CE11]: COMP: Pleas | e insert [38] |
| Formatted | [13] |
| Formatted | [14] |
| Formatted | [15] |
| Formatted | [39] |
| Comment [CE9]: AQ: Please che | eck the ([16] |
| Formatted | [40] |
| Formatted | [17] |
| Formatted | [18] |
| Formatted | [19] |
| Formatted | [20] |
| Formatted | [21] |
| Formatted | [22] |
| Formatted | [23] |
| Formatted | [24] |
| Formatted | [25] |
| Formatted | [26] |
| Formatted | [27] |
| Formatted | [28] |
| Formatted | [29] |
| Formatted | [41] |
| Formatted | [42] |
| Formatted | [43] |

albumin in the PJB-treated experimental population can also be due to dehydration, but the test is rarely used to diagnose dehydration as the other symptoms are clearer and more obvious. Drugs that increase albumin levels are insulin, growth hormones,osmotic diuretics,mannitol, and anabolic steroids [4443-4645].

Globulins are the key building block of antibodies. Globulins include gamma globulins (antibodies), beta globulins, alpha-2 globulins, and alpha-1 globulins and a variety of enzymes and carrier or transport proteins. Since the gamma fraction usually makes up the largest portion of the globulins, antibody deficiency should always come to mind when the globulin level is low [4746_4847].There is a very highly significant decrease of globulin in the PJB_ treated experimental population.Nephrosis, Emphysemaemphysema, Acute_nemolytic anemia, Liver______dysfunction, andHypogammaglobulinemiahypogammaglobulinemia

lead to low serum globulins level[4443,4645]. Considering the decrease in globulin content along with the noticeable lowering of total protein content in PJB-treated male rats, liver and kidney dysfunction might be a noteworthy point for further study.The liver can function adequately on 20% of liver tissue, thus early diagnosis by lablaboratory methods is difficult. A reversed A/G Ratio-ratio_may be a helpful indicator[4746,4842]. The normal A/G_ratio-ef albumin to globulin is usually between 1.7-2.2.-The significantly_high A/G ratio suggests underproduction of-immunoglobulins. An A/G ratio higher than 2.2 may indicate decreased thyroid function, low globulin, or an excess of glucocorticoids[4443,4645]. This can also prove to be an illuminating point for further scope of study.

Creatinine, an important part of muscle, is a breakdown product of creatine. The Alaboratory test is performed to measure the amount of creatinine in the blood to evaluate kidney function. In case of abnormal kidney function, creatinine levels will increase in the blood [4948. 5554]. Theincrease in the creatinine level in the serum of the male ratcould be due to renal insufficiency, decreased renal perfusion or reduced blood flow to the kidneys due to shock, dehydration, congestive heart failure, atherosclerosis, Skeletal -skeletal muscle trauma. ketonemiaor complications of diabetes, infection or autoimmune diseases, prostate disease, kidney stone, or urinary tract obstruction, pyelonephritis, death of cells in the kidneys' small tubes caused by drugs or toxins, or medications (Inhibit inhibit tubular secretion of Creatinine creatinine). Increased creatinine level in the blood suggests that kidney is having a compromised functional state [5655-6160].PJB should be used with caution in those individuals who are carrying any of the risk factors mentioned above.

Blood urea nitrogen (BUN) test is often carried out to check kidney function.BUN Increases increases by 10-20 function-is mg/dl/day, if-renal hindered; serum creatininelevel -is a better measure offor-renal function and BUN is reabsorbed at renal tubules [3433].Drugs like such as diuretics, aminoglycoside antibiotic, ganglionic angiotensin_converting blocker, enzyme inhibitor, cephalosporins, and hypervitaminosis D increaseBUN level in the serum and decrease the amount of urea excreted by the kidneys due to because of acute or chronic kidney dysfunction or failure, that which in turn increases the serum urea level [4443 4645]. So, PJB should be used with caution in those individuals with compromised kidney function as this causes the elevation in serum urea level

Uric acid is a chemical created when the body breaks down substances called purines, which are nitrogencontaining compounds found in the body in substances such as DNA. Most uric acid is removed from the body by the kidneys and is excreted in the urine; the remainder is eliminated in the stool. If too much uric acid is produced or not enough is excreted, it can accumulate in the body and cause increased levels in the blood (hyperuricemia) [4746_4847]. There are Ddrugs that can increase the level of uric acid in the body, like for example, alcohol, ascorbic acid, aspirin, caffeine, cisplatin, diazoxide, diuretics, epinephrine, ethambutol, levodopa, methyldopa, nicotinic theophylline 4443 acid. phenothiazines, and 4645].]. Thesignificant increase in the uric acid level in the serum of the PJB-treated population may be due tohypoparathyroidism, nephrolithiasis, polycythemia vera, and/or renal failure.

<<u>H1></u>CONCLUSION

From the above data obtained it can be concluded that PJB should not be administered chronically at a higher dose as it may cause kidney disease. Further studies should be done by reducing the dose administered dose.

<H1>ACKNOWLEDGEMENT

The authors are thankful to Focused Research on

Department of Pharmacy, and all faculty members and the technical staffs of the Department of Pharmacy, for their kind co-operation. We

would <u>The authors</u> express <u>our their</u> special thanks to Mr. for ensuring a constant supply of animals

and followed by also for the proper maintenance and care of these animals during all throughout the experimental period.

<u><TBL_CAP>Table 1:</u> Name of the ingredients/herbs used in the preparation of PijusaballiRasa (PJB)

| Formatted: Font: Not Bold |
|----------------------------|
| |
| Formatted: Font color: Red |
| Formatted: Font color: Red |
| Formatted: Font color: Red |
| |

| Formatted: Font color: Red |
|----------------------------|
| Formatted: Font color: Red |
| Formatted: Font color: Red |
| Formatted: Font color: Red |

Formatted: Font color: Red Comment [CE12]: AQ: Please check if the text "an important part of muscle" could be deleted in the sentence "Creatine" as creatine is a waste product from the muscles. Formatted: Font color: Red

Formatted: Font color: Red

Comment [CE13]: AQ: Please clarify if "ketonemiaor" be changed to "ketonemia"?

| 1 | Formatted: Font color: Red |
|----|--|
| -{ | Formatted: Font color: Red |
| A | Comment [CE14]: AQ: Table 1 has not been cited in the text. Please check. |
| λ | Formatted: Font: Not Bold |
| λ | Formatted: Font: Not Bold |
| 1 | Formatted: Font: Not Bold |
| 7 | Formatted: Font: Not Bold |

| <t head="">Name of ingredients</t> | Scientific/ Common_common_ name s | Parts used | Amount used |
|------------------------------------|---|-----------------------------------|------------------------|
| Sutaka (suddhaparada) | -Mercury(purified) | - | 6 g. |
| Gandhaka (suddha) | -Sulfur(purified) | - | 6 g. |
| Abhra (abhrakabhasma) | -Calcinedpurified mica ash | - | 6 g. |
| Tara (rajatabhasma) | -Silver ash(calcined silver) | - | 6 g. |
| Lauha (bhasma) | -Iron, Cinnabar cinnabar | - | 6 g. |
| Tangana (suddhatankana) | -Borax | - | 6 g. |
| Rasanjana (daruharidra) (Ext.) | Berberisaristata | Extract | 6 g. |
| Maksika (bhasma) | Chalcopyrite | - | 6 g. |
| Lavanga (Fl.) | Syzygiumaromaticum | Flower | 6 g. |
| Candana (svetacandana) (Ht. Wd.) | Santalum album | Wood | 6 g. |
| Musta (musta) (Rz.) | Cyperusrotundus | Rhizomes | 6 g. |
| Patha (Rt.) | Cissampelospareira | Root | 6 g. |
| Jiraka (Svetajiraka) (Fr.) | Cuminumcyminum | Flower | 6 g. |
| Dhanyaka (Fr.) | Coriandrumsativum | Flower | 6 g. |
| Samanga (Lajjalu) (Pl.) | Mimosa Pudica-<u>p</u>udica | Plant | 6 g. |
| Ativisa (Rt.) | Aconitum heterophyllum | Root | 6 g. |
| Lodhra (St. Bk.) | Symplocosracemosa | Stem <mark>Bark</mark> bark | 6 g. |
| Kutaja (St. Bk.) | Holarrhenaantidysenterica | Stem <mark>Bark<u>bark</u></mark> | 6 g. |
| Indrayava (Kutaja) (Sd.) | Holorrhenaantidysenterica | Seed | 6 g. |
| Tvaca (Tvak) (St. Bk.) | Cinnamimumzeylanicum | Stem <mark>Bark</mark> bark | 6 g. |
| Jatiphala (Sd.) | Myristicafragrans | Seed | 6 g. |
| Cirabilva (Fr. P.) | Holopteleaintegrifolia | Fr Patel | 6 g. |
| Kanaka bija (Suddhadhattura) (Sd.) | Daturastramonium | Seed | 6 g. |
| Dadimachada (dadima) (Fr. P.) | Punicagranatum | Fr Patel | 6 g. |
| Samanga (Lajjalu) (Pl.) | Mimosa Pudica | Plant | 6 g. |
| Dhataki (Fl.) | Woodfordiafruticosa | Flower | 6 g. Forma |
| Kustha (Rt.) | Saussurealappa | Root | 6 g. Forma |
| Kesaraja Rasa (bhrngaraja) (Pl.) | Eclipta alba | Plant | Q.S. for bhavana Forma |
| Chagidugdha (ajaksira) | -Goat's milk | | Q.S. for bhavana Forma |

| <pre><tbl_cap>Table 2:Effec</tbl_cap></pre> | t of PijusaballiR | asa (PJB) on Total <u>t</u>otal <mark>Serum</mark> | - <u>serum Proteinprotein</u> , Album | iin<u>albumin</u>, Globulin <u>glob</u> | <u>ulin</u> | 1 |
|---|----------------------------------|---|--|--|-------------|---|
| content, and albumin/glo | <u>obulin (</u> A/G <u>) rat</u> | <u>io in Male male Ratsrats.</u> | | | | Ľ |
| <t head="">Parameters</t> | Control | PIB | n value s | % Change | - | 2 |

| Total Protein | 54.2500 ± 1.01330 | 49.1250 ± 1.00778 | 0.003 | ↓9.45 <mark>%</mark> | |
|-------------------------------|---------------------------------|---|-------|----------------------|--|
| <u>protein(TP)</u> | | | | | |
| Albumin | 27.8750 ± 0.78916 | 34.7500 ± 1.98881 | 0.010 | 个24.66 % | |
| Globulin | 26.3750 ± 1.76208 | 14.3750 ± 2.33710 | 0.001 | ↓45.50 % | |
| A/G ratio | 1.1054 ± 0.10556 | 3.0419 ± 0.60785 | 0.015 | 个175.19 % | |
| <t_foot>个: increa</t_foot> | ase. ↓: decrease: *p≛ ≤ 0.05. * | **p <u>**</u> < 0.01, ***p <u>***</u> < 0.0 | 001 | | |

x + 10012 [. increase, ψ : decrease, μ = 30.00, μ = 30.01, μ = 20.001

| <t head="">Parameters</t> | Control | PJB | P-pvalues | % Change | • |
|-----------------------------------|--------------------------------|--|----------------------------------|---|------|
| ratio, and Uric uric Acid a | <u>cid level in male rats.</u> | | | | |
| <tbl_cap>Table 3:Effect</tbl_cap> | of PijusaballiRasa (PJB) o | n Creatinine<u>c</u>reatinine , <u>bioo</u> | <u>a urea hitrogen (</u> BUN), B | UN/ Creatinine <u>creati</u> | nine |

| | | | | , e enange |
|---|-------------------|-------------------|-------|----------------|
| Creatinine | 0.8250 ± 0.03660 | 0.8875±.02950 | 0.205 | 个7.58% |
| Blood Urea Nitrogen (BUN) | 11.0806 ± 0.53553 | 12.3248 ± 0.75419 | 0.200 | 个11.23% |
| BUN/ Creatinine<u>creatinine</u> | 13.5228 ± 0.66075 | 13.9944 ± 1.01103 | 0.702 | 个3.49% |
| Uric Acid<u>acid</u> | 1.9875 ± 0.08332 | 2.4875 ± 0.15861 | 0.014 | 个25.16% |
| | | | | |

| Formatted: Font: Not Bold |
|---|
| Formatted: Font: Not Bold |
| Formatted Table |
| Formatted: Font: Bold |
| Formatted: Font: Not Bold |
| Formatted: Font: Not Bold |
| Formatted: Font: Not Bold |
| officer i one not bold |
| Formatted: Font: Not Bold |
| Formatted: Font: Not Bold Formatted: Font: Not Bold |
| Formatted: Font: Not Bold Formatted: Font: Not Bold Formatted: Font: Not Bold Formatted: Font: Not Bold |
| Formatted: Font: Not Bold |
| Formatted: Font: Not Bold |

↑: increase, \downarrow : decrease; $\underline{*p^{*}} \le 0.05$, $\underline{**p^{**}} \le 0.01$, $\underline{***p^{***}} \le 0.001$

<H1>REFERENCES

<REF>1.__WHO,-_1977, 'Regional Office for the Western Pacific Seminar on the use of medicinal plants in health care'_Final____

Report, Tokyo, Japan. September 13–17.1977.

<REF>2.__WHO,-__2002,'WHO Launches launches the First_first_Global_global_Strategy_strategy_on Traditional_traditional_and

Alternative alternative Mmedicine', Press Release WHO/38, 16th-May 16.2002.

<REF>3.__WHO7._1999, 'Consultation Meeting meeting on Traditional traditional Medicine medicine and Modern modern

Medicinemedicine: Harmonizing harmonizing the Two two Approaches Geneva, World Health Organization,

Geneva, Geneva (document reference (WP) TM/ICP/TM/001/RB/98–RS/99/ GE/32(CHN). 1999.

<REF>4.__Ernst E., 2002,'Ayurvedic medicines.'-Pharmacoepidemiol Drug Saf. 2002; 11(6):455-456-.

<REF>5.__Anonymous_--1968,-Vaidya Yoga Ratnavali (Formulary-formulary of Ayurvedic medicines).-4MPCOPS, (The

Indian Medical Practitioner's Co-Operative Pharmacy & Stores Ltd), Madras xxii + 592 p. 1968.

+592 p.

<REF>6.__Anonymous,-__<u>1978a,'</u>Ayurvedic Formulary formulary of India, The (1978)' Government of India, Ministry of Health and Family Welfare, Department of Health, New Delhi-,_Volume I, Part I, firstFjirstedition, XXXVI and + 324 p. (2nd ed_Second

edition, part Part I, XLVI and + 488 p.,).1978a.

<REF>7.__Anonymous,-__<u>1978b</u>, 'Hand book of Ayurvedic and herbal medicines with formulae: with directory of manufacturers and suppliers of plants, equipment and machineries, packaging materials and raw materials suppliers', <u>Engineers India Research</u> Institute, Delhi, <u>1978</u>, XVIII, <u>4382 p. 1978b</u>.

<REF>8._Anonymous,--._<u>2005</u>,'Handbook of <u>Domestic_domestic_Medicine_medicine_</u>and <u>Common_common_</u>Ayurvedic <u>Remedies'remedies_</u>CentralCouncil for Research in Ayurveda and Siddha, New Delhi, <u>1978,</u>-XV + VI + 538 p, (reprint <u>Reprint2005</u>).2005.

<REF>9.__Anonymous., 2010,'Classical Ayurvedic Prescriptions-prescriptions for Common-common Diseases diseases (Only-only for registered

ayurvedic_Ayurvedic_medical practitioners}, Central Council for Research in Ayurveda and Siddha-,_Department of AYUSH, Ministry of Health &andFamily Welfare_Government ofIndia, New Delhi, xviii + 149 p.2010

<REF>10._Anonymous_, 2011a,'Ayurvedic Formulary_formulary_of India./The (2011)-Government of India, New Delhi./Volume

I, pPart 3, LXXVI and +710 p. 2011.

| Formatted: Font: 12 pt, Not Bold, Complex Script Font: 12 pt |
|---|
| Formatted: Font: Not Italic |

Formatted: Font: Not Italic

| Formatted: Font: Not Italic |) |
|-----------------------------|---|
| | |
| Formatted: Font: Not Italic |) |
| | |
| Formatted: Font: Not Italic |) |
| | |
| Formatted: Font: Not Italic |] |

| Formatted: Font: Not Italic |
|-----------------------------|
| Formatted: Font: Not Italic |
| Formatted: Not Highlight |
| Formatted: Font: Not Italic |
| Formatted: Not Highlight |
| Formatted: Font: Not Italic |
| Formatted: Not Highlight |
| Formatted: Font: Not Italic |
| Formatted: Not Highlight |
| Formatted: Font: Not Italic |

| <ref>11Anonymous 2011b.'Bangladesh National Formulary of Ayurvedic Medicine 1992 (Agpproved by the Government of</ref> | |
|--|--|
| Bangladesh vide Ministry of Health and Family Welfare, Memo No. Health-1/Unani-2/89/(Part-1) 116 dated 3-6-1991)-, National | Formatted: Font: Not Italic |
| Unaniand Ayurvedic Formulary Committee, Bangladesh Board of Unani and AyurvedicSystems of Medicine, 38, Bangabandhu | Formatted: Font: Not Italic |
| Avenue, Dhaka-1000. (Second edition-2011).2011b. | Formatted: Font: Not Italic |
| <ref>12Chatterjee T-K., 1993,'Handbook on Laboratory-laboratory Mice-mice and Rate'rats, Department of Pharmaceutical</ref> | |
| Technology, Jadavpur University ;(<mark>1st-First</mark> edi <u>tion);</u> , p.157. <u>1993.</u> | |
| <ref>13OECD Guideline (425) for the testing Testing of chemicals/<u>Chemicals/_2008, '</u>Guidance document on acute oral</ref> | |
| toxicity, Environmental environmental Health-health and Safety safety Monograph monograph Series-series on Testing testing | |
| and A <u>a</u> ssessment ', pp. 1-27 . 2008:pp. 1-27. | |
| <ref>14Tedeschi D-W-, Tedeschi R-E., 1968, Importance of Fundamental Principles of Drug Evaluation.</ref> | Formatted: Font: Not Italic |
| York: 307-324 . <u>1968: pp.307-324.</u> | |
| <ref>15Gad S-C.,1992,The Ratrat: Pathologypathology. In: Gad S-C-, Chengellis C-P-(eds-) Animal model Model</ref> | |
| in toxicology<u>T</u>oxicology Marcel Dekker, New York , USA . <u>1992.</u> | Formatted: Font: Not Italic |
| <ref>16Weingand K-, et al.,1996, Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint</ref> | |
| Scientific Committee for International Harmonization of Clinical Pathology Testing | Formatted: Font: Not Italic |
| andAppliedToxicology_1996;29:198-201. | Formatted: Font: Not Italic |
| <ref>17Kinter L.B., Gossett K.A., Kerns W.D.,1994, 'Status of safety pharmacology in the pharmaceutical industry.'-Drug</ref> | Formatted: Font: Not Italic |
| DevelopmentResearch-Res.1994;32:208-216. | Formatted: Font: Not Italic |
| <ref>18. ICH S7A., 2000, 'Safety pharmacology studies for human pharmaceuticals.' Geneva: International Conference for</ref> | Formatted: Font: Not Italic |
| Harmonization, <u>Geneva</u> . 2000. | Formatted: Font: Not Italic |
| <ref>19SeuterF.,1996, 'Safety pharmacology studies.' Scandinavian Journal of Laboratory AnimalScienceSci.1996;23:297-304.</ref> | Formatted: Font: Not Italic |
| <ref>20Stevens KR, Gallo MA.1989, 'Practical consideration in the conduct of chronic toxicity studies.'-Principles and Methods</ref> | Formatted: Font: Not Italic |
| of Toxicology, 2nd-Second ed <u>itio</u> n-, Chap-ter VIII. <u>1989.</u> | Formatted: Font: Not Italic |
| <ref>21Garner R-J.,1957, 'Veterinary ToxicologyBalliereTindall, London.<u>1957.</u></ref> | Formatted: Font: Not Italic |
| <ref>22Clarke M-L-, Harvey D-G-, Humphrey D-J., 1981, 'Veterinary Toxicology-, 2nd-Second edition.' Bailliere Tindall, London,</ref> | Formatted: Font: Not Italic |
| <u>1981: pp_</u> + 219. | Formatted: Font: Not Italic |
| <ref>23Sikula J.,1981,'Veterinary Toxicology (Developments in animal and veterinary science, 7).</ref> | |
| Ed <u>ited-By by Bartik M₂-and-</u> Piskac A- ₂ Elsevier Scientific Publishing Company, New York. <u>1981.</u> | Formatted: Font: Not Italic |
| <ref>24Coles E.,1974, 'Veterinary clinical <u>Clinical pathology</u>Pathology', 2nd <u>Second</u>ed<u>ition</u>, Philadelphia, London, 1974</ref> | Comment [CE15]: AQ: Please provide the publisher name for Reference 24. |
| | Formatted: Font: Not Italic |

<REF>25. Duncan J_rR_r, Prasse K_rW_r, Mahaffey E_rA., <u>1994</u>, Veterinary Laboratory Medicine (Clinical Pathology)², lowa State Formatted: Font: Not Italic University Press, Iowa, 1994, Formatted: Font: Not Italic Formatted: Font: Not Italic <REF>26. Levine B₇S., 1995, 'Animal clinical pathology.In: CRC handbook of toxicology, ed. M.J. Derelanko. MJ and M.A. Hollinger Formatted: Font: Not Italic MA² (eds). CRC Handbook of Toxicology, Boca Raton, FL, CRC Press, Boca Raton, FL. 1995; pp. 517-537. Formatted: Font: Not Italic <REF>27. Knoll JrS.,1998, 'Diagnostic procedures for the private practice laboratory.³⁷ In: Aiello SrE+ (Eded.).³⁷ Merck Veterinary Formatted: Font: Not Italic Comment [CE16]: AQ: Reference 28 missing, so Manual², Merck & Co., Inc., New Jersey. 1998; pp., 1193-1196. the other references have been renumbered from here. The corresponding renumbering has been done <REF>2928. __Tomaszewski K-E.,1993,Application of <u>Animal_animal_Toxicology_toxicology_Data_data_</u>to Clinical_clinical in text citations too. Please check. Formatted: Font: Not Italic Study-study of Experimental experimental Drugsdrugs Medicine Comparative Haematology International. 1993;3(2):67-70. Formatted: Font: Not Italic _Kelly W-R_(ed.).,1984, 'In: Veterinary and clinical_Clinical diagnosisDiagnosis, 2 Schalm O., 1975. Veterinar <REF>3029. Formatted: Font: Not Italic Formatted: Font: Not Italic Haematology', 3^{re}ed<u>Third edition</u>. Lea, Kelly W.R. eds. BaillierTrindall, London. <u>1984</u>; pp. 260-300. Formatted: Font: Not Italic <REF>3130. _Eastham R.,1982, 'Clinical Haematology', 5th ed.<mark>Fifth edition.,</mark>Brittney Press (Year Book Publishers), Bath, Formatted: Font: Not Italic Comment [CE17]: AQ: Please check if England 1982. Reference 29 has been set correctly. <REF>3231._____Howard E-B-,Matsumato G.,1997, 'Laboratory procedures.In: Catcott- E-J- (ed.).Animal health Health Formatted: Font: Not Italic Formatted: Font: Not Italic egy <u>Technology</u> (formerly animal <u>Animal hospital Hospital techr</u> plogyTechnology).², 2nd-ed.Second edition.,Catcott, E.J. Formatted: Font: Not Italic (ed.). American Veterinary Publications, Inc., USA 1997; pp. 227-258. Formatted: Font: Not Italic Formatted: Font: Not Italic <REF>3332. _Pratt D.S.,2010, 'Liver chemistry and function tests. In: Feldman M, Friedman LS, Brandt LJ, Formatted: Font: Not Italic [Eds-eds], Sleisenger and Fordtran's Gastrointestinal and Liver Disease. _ Oth edNinth edition, Chapter 73, Philadelphia, Comment [CE18]: AQ: Please provide the city of publication for Reference 31. Pa:Saunders Elsevier, Philadelphia, PA; chap 73.2010, Formatted: Font: Not Italic Formatted: Font: Not Italic <REF>3433. _Clarkson MR, Friedewald JJ, Eustace JA, Rabb H. Acute kidney injury. In: Brenner BM7(ed.)s. Brenner and Formatted: Font: Not Italic Rector's The Kidney-, 8th-Eighthed.edition, Chapter 29.Pa:-Saunders Elsevier, Philadelphia, PA. ; chap 29, Philadelphia, USA: Formatted: Font: Not Italic 2008. Formatted: Font: Not Italic Formatted: Font: Not Italic <REF>3534. Doumas BT. Clin chem, 1975; 'Standards for total serum protein assays-: a collaboration Formatted: Font: Not Italic study.<u>-</u>Clinicalchemistery_Chem.1975;21:1159-1166. Formatted: Font: Not Italic Formatted: Font: Not Italic <REF>3635. _Doumas B₇T₇, Watson W₇A₇, Biggs H₂G., 1971,'Bromacresol green method for quantitative determination of Formatted: Font: Not Italic albumin in serum.'-Clin-Chim-Acta. 1971;31:87-96. Formatted: Font: Not Italic Formatted: Font: Not Italic _Bartels H, Böhmer M.;1971, 'Micro-determination of creatinine<u>.'</u>ClinChimActa.Mar;1971;32(1):81-85. <REF>3736. Formatted: Font: Not Italic <REF>3837. _Tabacco A-, Meiattini F-, Moda E-, Tarli P.,1979, 'Simplified enzymic/colorimetric serum urea nitrogen Formatted: Font: Not Italic determination. ClinChem. Feb 1979;25(2):336-337. Formatted: Font: Not Italic Formatted: Font: Not Italic

Formatted: Font: Not Italic Formatted: Font: Not Italic

<REF>39<u>38</u>.__

| aminophenazonechromogenic system in direct enzymic assay of uric acid in serum and urine. <u>Clin Chem. Feb1980</u> 26(2):227- | _(|
|--|----------------------|
| 231. | |
| <ref>4039Hoffman R-, Benz E-J-Jr-, Shattil S-J-, et al., (eds), (2008,-Hoffman Hematology: Basic Principles and Practice-</ref> | |
| ² 5th <u>Fifthed.⁴edition, Chapter 87.</u> , Philadelphia, Pa:Churchill Livingstone Elsevier, Philadelphia, PA: chap 87.2008, | |
| <ref>4140Alper C.A.,1974, 'Plasma protein measurement as a diagnostic aid.'_N-Eng. J. Med. 1974, 291:287-290.</ref> | 4 |
| <ref>4241Naganna B.,1989, 'Plasma proteins. In: <u>Talwar GP, Srivastava LM,Moudgil KD(eds).</u> Textbook of Biochemistry</ref> | |
| and Human Biology, 2nd Second |] |
| edition. ed. Talwar G.P., Srivastava L.M. and Moudgil K.D. ' _a Prentice-Hall of India Private PvtLtd., New- Delhi÷.1989: pp. 59-61. | |
| <ref>4342Pratt D.S.,2010,-Liver chemistry and function tests. In: Feldman M, Friedman LS, Brandt LJ,</ref> | $ \lambda$ |
| Eds'(eds). Sleisenger and Fordtran's Gastrointestinal and Liver DiseaseSth- <u>Ninthededition, Chapter 73, Philadelphia, Pa</u> : | 4 |
| Saunders Elsevier <u>, Philadelphia, PA: chap 73.2010</u> | |
| <ref>44<u>43</u>Wallach J.,2006, "Interpretation of Diagnostic Tests², 8th edEighth edition.,Lippincott Williams & Wilkins</ref> | |
| 2006, ISBN: 9780781730556: 1200 p. | 1 |
| <ref>4544Kaplan M-M.,1983, 'Clinical chemistryChemistry: Interpretation and Techniques, 2nded'Second edition.sLea</ref> | $\langle \rangle$ |
| and FebigerPublication, Philadelphia <u>, PA 1983: pp. 1</u> 58-160. | \backslash |
| <ref>4645Bush B.M.,1991, 'Interpretation of laboratory_Laboratory_results_Results_for small_Small_animal_Animal</ref> | |
| clinicians <u>Clinicians</u> . ² Blackwell | |
| Scientific Publications, Oxford. <u>1991</u> | X |
| <ref>4746Zilva J.F., Panmall P.R., Mayne P.D., 1991, Clinical Chemistry in Diagnosis and Treatment, Sthedition' Fifth</ref> | $\overline{\langle}$ |
| edition England Clays Ltd., St. Ives Plc., England. <u>1991.</u> | -{ |
| <ref>4847Marks V-, Cantor Th-, Mesko D-, et al., 2003, 4 Differential Diagnosis by Laboratory Medicine. 4 Springer-Verlag.</ref> | |
| <u>Berlin, 2003. JSBN: 9783540430575: 1106.</u> | |
| <ref>49<u>48</u>Zalups R-K-, Lash L-H.,1996, 'Methods in renal <u>Renal</u> toxicology <u>Toxicology</u> <u>Boca Raton, FL: CRC Press, <u>Boca</u></u></ref> | \sum |
| Raton, FL <u>1996.</u> | |
| <ref>5049. Price R:G-, et al.,1996, 'Development and validation of new screening tests for</ref> | -(|
| nephrotoxic Effects/effects Hum an and Exp erimental Toxicol_ ogy1996_ 15(suppl-1):S10– <u>S</u> 19. | |
| <ref>51<u>50.</u> Price R-G.,2002, 'Early markers of nephrotoxicity.' ComparativeClinicalPathology_Path.2002, 11:2-7.</ref> | $\langle \langle$ |

_Fossati P., Prencipe L., Berti G., 1980, ⁽Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-

Formatted: Font: Not Italic Comment [CE19]: AQ: Please provide the publisher location for Reference 43. Formatted: Font: Not Italic Formatted: Font: Not Bold Formatted: Font: Not Italic Formatted: Font: Not Italic

| <ref><mark>5251. Mitchell F.L., Veall N.,Watts R.W.E.,1972, '</mark>Renal function tests suitable for</ref> | | |
|---|------------|-----------------------------|
| clinicalpractice Ann-Clin-Biochem. 1972;9:1-20. | | Formatted: Font: Not Italic |
| <ref>5352. BoyeeK-C1986'Renal function and laboratory evaluation.'ToxicologicPathology 1986:14:26-26.</ref> | | Formatted: Font: Not Italic |
| | < | Formatted: Font: Not Italic |
| <ref>5453. Loeb W-F.,1998, 'The measurement of renal injury '-, Toxicologic Pathology. 1998; 26:26-28.</ref> | | Formatted: Font: Not Italic |
| <ref>5554Kluwe W-M.,(1981, 'Renal function tests as indicators of kidney injury in subacute toxicity</ref> | \searrow | Formatted: Font: Not Italic |
| studies / Tavisalam and Applied Depressalam, 1001/57/414-424 | Y | Formatted: Font: Not Italic |
| studiesToxicology and Applied Pharmacology.1301_37.414-424. | < (| Formatted: Font: Not Italic |
| <ref>5655Gray J-E(1977.)^CChronic nephrosis in the albino rat.²CRC Critical Reviews in Toxicology1977;5:115-144.</ref> | | Formatted: Font: Not Italic |
| ADED FREC Fretty Marine F. Zhinden C. (1999) (Markasterisity assessing in staty A subjective study (Assbirg | \searrow | Formatted: Font: Not Italic |
| < KEr> 57 <u>56</u> . FentK-, Mayer E-, Zoinden G., (1988, N ephrotoxicity screening in fats: A- <u>a</u> validation study- <u>A</u> rch wes | | Formatted: Font: Not Italic |
| efToxicole gy.1988; 61:349-358. | | Formatted: Font: Not Italic |
| CREENEDER Lauwany R. Barnard A. (1000, 'Practinical dataction of nonhrotoxicity: Description description of the test | | Formatted: Font: Not Italic |
| CREP-36_7Ladwerys R., Bernard A., 1965, - Predimical detection of nephrotoxicity. Description description of the test | | |
| and appraisal oftheir health significance. ⁴ Toxicol ogy Lett ers.1989. 46: 13-29. | | Formatted: Font: Not Italic |
| <ref>5958. Stonard M-D..(1990. 'Assessment of renal function and damage in animal species.'-Journalof</ref> | | Formatted: Font: Not Italic |
| | | Formatted: Font: Not Italic |
| Appl ied Toxicol ogy.1990; 10: 267-274. | (| Formatted: Font: Not Italic |
| <ref>6059. Stonard M-D.,(1996, 'Assessment of nephrotoxicity, In:<u>Evans GO (ed.).</u>Animal clinical</ref> | (| Formatted: Font: Not Italic |
| chemistry<u>Chemistry</u>. A <u>primer Primer</u> for | | |
| Toxicologists , ed. Evans G.O., London', Taylor & Francis Ltd., London. 1996; pp. 87-98 | | Formatted: Font: Not Italic |
| <ref>6460. Palm M., Lundblad A., (2005) Creatining concentration in plasma from dog, rat and mouse: A-acomparison</ref> | \searrow | Formatted: Font: Not Italic |
| sher zerzy unit Mi, catabled A. Acoos, creating concentration in plasma from dog, rat and mouse. A g eomparison | - Y | Formatted: Font: Not Italic |

ofthree different methods.-VeterinaryClinical Pathology.2005;34: 232-236.

Formatted: Font: Not Italic Formatted: Font: Not Italic Formatted: Font: Not Italic Formatted: Font: Not Italic Formatted: Font: Not Italic

| Page 3: [1] Formatted | CE | 6/29/2020 8:55:00 AM |
|--|--|--------------------------------------|
| Font color: Red | | |
| Page 3: [2] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [3] Formatted | CE | 6/28/2020 12:26:00 PM |
| Font: Not Italic | | |
| Page 3: [4] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [5] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [6] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [7] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [8] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [9] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [10] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [11] Formatted | CE | 6/28/2020 12:26:00 PM |
| Font: Not Italic | | |
| Page 3: [12] Formatted | CE | 6/29/2020 11:25:00 AM |
| Font: Italic | | |
| Page 3: [13] Formatted | CE | 6/28/2020 12:16:00 PM |
| Font: Not Italic | | |
| Page 3: [14] Formatted | CE | 6/28/2020 12:16:00 PM |
| Font: Not Italic | | |
| Page 3: [15] Formatted | CE | 6/28/2020 12:16:00 PM |
| Font: Not Italic | | |
| Page 3: [16] Comment [CE9] | CE | 6/29/2020 12:44:00 PM |
| AQ: Please check the changes made to the | e sentence "According to the OECD test | guideline 425 was conducted" are OK. |
| Page 3: [17] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Italic, (| Complex Script Font: Vrinda | |
| Page 3: [18] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Italic, O | Complex Script Font: Vrinda | |
| Page 3: [19] Formatted | CE | 6/28/2020 12:17:00 PM |

Font: (Default) Calibri, Not Italic, Complex Script Font: Vrinda

Font: (Default) Calibri, Not Italic, Complex Script Font: Vrinda

| Page 3: [21] Formatted | CE | 6/28/2020 12:17:00 PM |
|--|---------------------------------|-----------------------------|
| Font: (Default) Calibri, Not Itali | c, Complex Script Font: Vrinda | |
| Page 3: [22] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Itali by | c, Complex Script Font: Vrinda, | Not Expanded by / Condensed |
| Page 3: [23] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Itali by | c, Complex Script Font: Vrinda, | Not Expanded by / Condensed |
| Page 3: [24] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Itali by | c, Complex Script Font: Vrinda, | Not Expanded by / Condensed |
| Page 3: [25] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Itali by | c, Complex Script Font: Vrinda, | Not Expanded by / Condensed |
| Page 3: [26] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Itali by | c, Complex Script Font: Vrinda, | Not Expanded by / Condensed |
| Page 3: [27] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Itali | c, Complex Script Font: Vrinda | |
| Page 3: [28] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Itali | c, Complex Script Font: Vrinda | |
| Page 3: [29] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: (Default) Calibri, Not Itali | c, Complex Script Font: Vrinda | |
| Page 3: [30] Comment [CE10] | CE | 6/29/2020 12:44:00 PM |
| COMP: Please insert Table 2 near here | 2. | |
| Page 3: [31] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: Not Italic | | |
| Page 3: [32] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: Not Italic | | |
| Page 3: [33] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: Not Italic | | |
| Page 3: [34] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: Not Italic | | |
| Page 3: [35] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: Not Italic | | |
| Page 3: [36] Formatted | CE | 6/28/2020 12:17:00 PM |
| Font: Not Italic | | |
| | | |

| Page 3: [38] Comment [CE11] | CE | 6/29/2020 12:44:00 PM |
|--|----|-----------------------|
| COMP: Please insert Table 3 near here. | | |
| Page 3: [39] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [40] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [41] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [42] Formatted | CE | 6/29/2020 8:55:00 AM |
| Font color: Red | | |
| Page 3: [43] Formatted | CE | 6/29/2020 8:56:00 AM |
| Font color: Red | | |